̽���ϼ�

SOMERSET, N.J. – January 16, 2020 — ̽���ϼ�, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer. Ms. Flynn has also joined the company’s Executive Leadership Team and will report to Alessandro Maselli, ̽���ϼ�’s President and Chief Operating Officer. Ms. Flynn takes on the role previously held by Mr. Barry Littlejohns, who will be retiring.

Ms. Flynn assumes global responsibility for ̽���ϼ�’s biologics business, including the several investments and expansions currently taking place, which include a $200 million capital investment to expand drug substance manufacturing capacity in Madison, Wisconsin and drug product fill/finish capacity in Bloomington, Indiana. Ms. Flynn will also spearhead commercial excellence across the entire company.

In addition, ̽���ϼ� has promoted Mike Riley to Region President, Biologics North America, and appointed Manja Boerman as Region President, Biologics Europe, where each will lead all development, manufacturing, and commercial activity in their respective regions, as well as growing ̽���ϼ� Biologics’ business. Mr. Riley has been with ̽���ϼ� for nearly 15 years and previously served as Vice President/General Manager of ̽���ϼ� Biologics. In his new role, Mr. Riley will oversee the sites in Bloomington and Madison, as well as Emeryville, California, and the company’s Biologics operations at its facilities in Research Triangle Park, North Carolina, and Kansas City, Missouri. Ms. Boerman joined ̽���ϼ� in December 2019 from her previous role as President of Aesica Pharmaceuticals, and has over 20 years’ experience in biotech and pharmaceutical services. She will oversee the company’s European biologics sites, including Brussels, Belgium and its newly acquired site in Anagni, Italy, which is a state-of-the-art facility for late-phase tech transfers and commercial product launches. Both Ms. Boerman and Mr. Riley have also joined ̽���ϼ�’s Executive Leadership Team and report directly to Ms. Flynn.

Pete Buzy will continue to lead ̽���ϼ�’s Gene Therapy business, where, under his guidance, ̽���ϼ� has been investing significantly in capacity, equipment, and expertise needed to meet strong and growing demand for custom development and manufacturing of adeno-associated virus (AAV) vectors, next-generation vaccines, and oncolytic viruses.

Ms. Flynn has over 30 years’ experience in commercial, operations, and general management roles within the pharmaceutical services industry, and she rejoins ̽���ϼ� after more than 11 years, having previously spent eight years as part of Cardinal Health/̽���ϼ� in various commercially focused roles. Her most recent position was Senior VP and Chief Commercial Officer for West Pharmaceutical Services. Ms. Flynn holds two master’s degrees: in engineering from the University of Pennsylvania, and in business administration from Boston University; as well as a Bachelor of Science in Pre-Professional studies from the University of Notre Dame.

“We welcome Karen back to ̽���ϼ� in a role that allows her to use her extensive talents and experience as we deliver to our customers advanced, crucial pharmaceutical research and development services, as well as commercial supply,” commented Mr. Maselli. “Karen arrives during a period of strong growth both in the biologics business and across the company as a whole, during which we are investing hundreds of millions of dollars in our biologics business and strengthening our commitment to ensuring that our customers have access to the best possible advanced biologic development technology and manufacturing solutions, from DNA through to clinical and commercial supply.” He added, “We would like to thank Barry, who has given more than three decades of service to the company and, in particular, led our initial efforts to expand our biologics drug substance, drug product, and gene therapy businesses.”

Notes For Editors

ABOUT CATALENT

̽���ϼ�, Inc. (NYSE:CTLT) is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, ̽���ϼ� has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. ̽���ϼ� employs over 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. ̽���ϼ� is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

More products. Better treatments. Reliably supplied.™

FORWARD-LOOKING STATEMENTS

This release contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements concerning the future growth and prospects of the Company’s biologics business segment. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “foresee,” “likely,” “may,” “will,” “would” or other words or phrases with similar meanings. Similarly, statements that describe the Company’s objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from ̽���ϼ�, Inc.’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: participation in a highly competitive market and increased competition may adversely affect the business of the Company; demand for the Company’s offerings, which depends in part on the Company’s customers’ research and development and the clinical and market success of their products; product and other liability risks that could adversely affect the Company’s results of operations, financial condition, liquidity and cash flows; failure to comply with existing and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on the Company’s business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex services or support required; global economic, political and regulatory risks to the operations of the Company; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights, trademarks and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products the Company manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rate of the U.S. dollar against other currencies, including as a result of the U.K.’s pending exit from the European Union; adverse tax legislative or regulatory initiatives or challenges or adjustments to the Company’s tax positions; loss of key personnel; risks generally associated with information systems; inability to complete any future acquisitions and other transactions that may complement or expand the Company’s business or divestment of non-strategic businesses or assets and difficulties in successfully integrating acquired businesses and realizing anticipated benefits of such acquisitions; risks associated with timely and successfully completing, and correctly anticipating the future demand predicted for, capital expansion projects at our existing facilities, offerings and customers’ products that may infringe on the intellectual property rights of third parties; environmental, health and safety laws and regulations, which could increase costs and restrict operations; labor and employment laws and regulations or labor difficulties, which could increase costs or result in operational disruptions; additional cash contributions required to fund the Company’s existing pension plans; substantial leverage resulting in the limited ability of the Company to raise additional capital to fund operations and react to changes in the economy or in the industry, exposure to interest-rate risk to the extent of the Company’s variable-rate debt and preventing the Company from meeting its obligations under its indebtedness. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019, filed August 27, 2019. All forward-looking statements speak only as of the date of this release or as of the date they are made, and ̽���ϼ�, Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law.